Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. and its executives due to significant stock price drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and Sections 11 and 15 of the Securities Act of 1933 [3]. - Investors have until March 6, 2026, to request to lead the case in the U.S. District Court for the Southern District of New York [3]. Group 2: Company Background - Fermi Inc. is an energy and AI infrastructure company aiming to build large-scale nuclear reactors to support grid-independent data centers for AI companies [4]. - The company's flagship project, Project Matador, is designed to provide dedicated power for AI workloads [4]. Group 3: IPO and Allegations - Fermi completed its IPO in October 2025, claiming strong demand for Project Matador and securing a 20-year lease with an investment-grade-rated tenant [5]. - Allegations suggest that Fermi overstated tenant demand and misrepresented the agreement with the First Tenant [6]. Group 4: Stock Price Impact - Following the announcement of the First Tenant's termination of the construction agreement on December 11, 2025, Fermi's stock dropped by $5.16, or over 33%, from $15.25 to $10.09 per share [7].

Core Viewpoint - A securities fraud class action lawsuit has been filed against PayPal Holdings, Inc. for allegedly making materially false and misleading statements regarding its business operations and revenue outlook during the specified class period [2][4]. Group 1: Lawsuit Details - The lawsuit is titled Goodman v. PayPal Holdings, Inc., et al, and was filed in the United States District Court for the Northern District of California [2]. - The class period for the lawsuit is from February 25, 2025, to February 2, 2026, and investors have until April 20, 2026, to file for lead plaintiff status [6]. - Allegations include that PayPal's management misrepresented the company's projected revenue and growth, downplaying risks associated with seasonality and macroeconomic factors [4]. Group 2: Stock Performance - On February 3, 2026, PayPal announced a leadership change, replacing its CEO, which coincided with the release of its fourth quarter and full year 2025 earnings report [5]. - The earnings report revealed that PayPal missed consensus estimates for both revenue and profit, leading to a significant stock price drop of $10.63, or 20.3%, closing at $41.70 per share [5]. Group 3: Investor Actions - Investors who purchased PayPal common stock and experienced losses are encouraged to contact Kessler Topaz Meltzer & Check, LLP for potential recovery options [3][6]. - The firm offers a free case evaluation and operates on a contingency fee basis, meaning there is no upfront cost to the investors [7].

Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. and its executives due to significant stock price drops linked to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled Lupia v. Fermi Inc., et al., No. 1:26-cv-00050 [3]. - Investors have until March 6, 2026, to request to lead the case, asserting securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and Sections 11 and 15 of the Securities Act of 1933 [3]. Group 2: Company Background - Fermi Inc. is an energy and AI infrastructure company aiming to build large-scale nuclear reactors to support grid-independent data centers for AI companies [4]. - The company's flagship project, Project Matador, is designed to provide dedicated power for AI workloads [4]. Group 3: IPO and Allegations - Fermi completed its IPO in October 2025, claiming strong demand for Project Matador and securing a 20-year lease with an investment-grade-rated tenant [5]. - Allegations suggest that Fermi overstated tenant demand and misrepresented the agreement with the First Tenant [6]. Group 4: Stock Price Impact - On December 12, 2025, Fermi's stock dropped by $5.16 per share, over 33%, following the termination of the Advance in Aid of Construction Agreement by the First Tenant [7].

Core Viewpoint - A class action lawsuit has been filed against NuScale Power Corporation and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - NuScale Power Corporation is a nuclear technology company known for its NuScale Power Module (NPM), a small modular nuclear reactor designed for energy generation within larger power plants [4]. Allegations and Background - The lawsuit claims that NuScale misrepresented its partnership with ENTRA1 Energy LLC, asserting that ENTRA1 had extensive capabilities and experience in developing power plants, which was allegedly false [5][6]. - ENTRA1 is described as having no significant experience in building nuclear power projects and primarily supporting the activities of its principal, Wadie Habboush [6]. Financial Impact - On November 6, 2025, NuScale reported a dramatic increase in general and administrative expenses from $17 million in the previous year to $519 million in Q3 2025, largely due to a $495 million payment to ENTRA1 [7]. - Following the disclosure of ENTRA1's lack of experience, NuScale's stock price fell by $4.03 per share, a decline of over 12.4%, from $32.46 to $28.43 between November 6 and November 10, 2025 [7].

Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. and its executives due to significant stock drop linked to potential violations of federal securities laws [1][3]. Company Overview - Fermi Inc. is an energy and AI infrastructure company aiming to build large-scale nuclear reactors to support grid-independent data centers for AI companies [4]. - The company's flagship project is Project Matador, designed to provide dedicated power for AI workloads [4]. IPO and Allegations - Fermi completed its IPO in October 2025, claiming strong demand for Project Matador and securing a 20-year lease with an investment-grade-rated tenant [5]. - Allegations suggest that Fermi overstated tenant demand and misrepresented the agreement with the First Tenant [6]. Stock Performance - Following the announcement of the First Tenant's termination of the Advance in Aid of Construction Agreement on December 11, 2025, Fermi's stock dropped by $5.16, or over 33%, from $15.25 to $10.09 per share [7].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is filed in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022 [3]. - Investors have until March 9, 2026, to request to be appointed to lead the case, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections" while actually using a "180-day cliff" method [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health disclosed a $43 million revenue decrease for the quarter and increased professional liability reserves by $54 million, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].

Core Viewpoint - A class action lawsuit has been filed against NuScale Power Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Oregon, captioned Truedson v. NuScale Power Corporation, et al., No. 3:26-cv-00328 [3]. - Investors have until April 20, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - NuScale Power Corporation specializes in nuclear technology, particularly the NuScale Power Module (NPM), a small modular nuclear reactor designed for energy generation [4]. - The company had established a partnership with ENTRA1 Energy LLC, which was responsible for constructing power generation facilities using NuScale's NPMs [4]. Group 3: Allegations Against ENTRA1 - NuScale allegedly misrepresented ENTRA1's capabilities, claiming it had extensive experience in developing power plants, while in reality, ENTRA1 had never built or operated any significant projects [5][6]. - ENTRA1 was primarily organized to support the activities of its principal, Wadie Habboush, rather than to independently manage power plant projects [6]. Group 4: Stock Price Impact - On November 6, 2025, NuScale reported a dramatic increase in general and administrative expenses from $17 million to $519 million in 3Q 2025, largely due to a $495 million payment to ENTRA1 [7]. - Following the disclosure of ENTRA1's lack of experience, NuScale's stock price fell by $4.03 per share, a decline of over 12.4%, from $32.46 to $28.43 between November 6 and November 10, 2025 [7].

Agilon Health Deadline: AGL Investors with Losses in Excess of $100K Have Opportunity to Lead agilon health, inc. Securities Fraud Lawsuit First Filed by the Rosen Law Firm [Accessibility Statement] Skip NavigationNEW YORK, Feb. 20, 2026 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of agilon health, inc. (NYSE: AGL) between February 26, 2025 and August 4, 2025, both dates inclusive (the "Class Period"), of the important March 2, 2026 lead plaintiff ...

Core Viewpoint - Inovio Pharmaceuticals, Inc. is facing a class action lawsuit due to alleged securities fraud, with a deadline for shareholders to file a lead plaintiff motion by April 7, 2026. The lawsuit claims that the company made misleading statements regarding its product development and regulatory prospects, leading to significant stock price declines [1]. Summary by Relevant Sections Company Performance - Inovio's stock price fell by $0.27 (3.1%) to close at $8.44 per share on August 9, 2024, following the announcement of a delay in submitting the Biologics License Application (BLA) for INO-3107 due to manufacturing issues [1]. - On December 29, 2025, the stock price dropped by $0.56 (24.45%) to close at $1.73 per share after the FDA accepted the INO-3107 BLA on a standard review timeline instead of the anticipated accelerated review [1]. Legal Proceedings - The class action lawsuit alleges that Inovio's management made materially false and misleading statements and failed to disclose adverse facts about the company's operations and prospects during the class period from October 10, 2023, to December 26, 2025 [1]. - Specific allegations include deficiencies in the manufacturing of Inovio's CELLECTRA device, the unlikelihood of timely BLA submission, and overstated regulatory and commercial prospects for INO-3107 [1]. Investor Actions - Shareholders who suffered losses during the class period are encouraged to contact Glancy Prongay Wolke & Rotter LLP to potentially pursue claims under federal securities laws [1].

Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? Affected uniQure N.V. Investor Summary Who: uniQure N.V. (NASDAQ: QURE)What: Securities fraud class action lawsuit filedClass Period: September 24, 2025, and October 31, 2025Deadline to Seek Lead Plaintiff Status: April 13, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s Huntington’s disease gene therapy drug.Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.c ...